Clinical Trial Update: Predictors of Non-response and Loss of Response in IBD Patients Treated With Anti-TNF

View source ↗

Summary

This clinical trial update examines factors that predict non-response and loss of response to anti-TNF therapy in patients with inflammatory bowel disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Certolizumab pegol (certolizumab pegol)
• Golimumab (golimumab)
• Infliximab (infliximab)

Snippet

Sponsor: Evangelismos Hospital | Conditions: Inflammatory Bowel Disease | Status: COMPLETED